Triumph Capital Management Has $273,000 Stake in Pfizer Inc. (NYSE:PFE)

Triumph Capital Management grew its position in Pfizer Inc. (NYSE:PFE) by 20.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,283 shares of the biopharmaceutical company’s stock after purchasing an additional 1,717 shares during the quarter. Triumph Capital Management’s holdings in Pfizer were worth $273,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Park Avenue Securities LLC grew its position in Pfizer by 11.4% during the fourth quarter. Park Avenue Securities LLC now owns 106,050 shares of the biopharmaceutical company’s stock worth $2,814,000 after buying an additional 10,824 shares in the last quarter. Tallon Kerry Patrick acquired a new stake in Pfizer during the fourth quarter worth approximately $509,000. Empirical Asset Management LLC grew its position in Pfizer by 383.4% during the fourth quarter. Empirical Asset Management LLC now owns 49,622 shares of the biopharmaceutical company’s stock worth $1,316,000 after buying an additional 39,356 shares in the last quarter. Wealthcare Advisory Partners LLC grew its position in Pfizer by 1.5% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 155,044 shares of the biopharmaceutical company’s stock worth $4,113,000 after buying an additional 2,324 shares in the last quarter. Finally, Walker Asset Management LLC grew its position in Pfizer by 4.6% during the fourth quarter. Walker Asset Management LLC now owns 11,598 shares of the biopharmaceutical company’s stock worth $308,000 after buying an additional 513 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of analyst reports. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price on the stock. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Stock Up 1.0%

Shares of PFE opened at $22.83 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The stock has a market capitalization of $129.77 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a fifty day moving average of $23.65 and a 200-day moving average of $25.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the company earned $0.82 EPS. Pfizer’s revenue was down 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. Pfizer’s payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.